CBIS News is out CBIS news out -- Cannabis Scienc
Post# of 1193
(Total Views: 221)
Posted On: 05/11/2017 9:08:37 AM
CBIS News is out
CBIS news out -- Cannabis Science Releases First Test Batch of Suppositories to Aid Self-Medicating Patients That Require Alternative Delivery Methods With Severe Pain and Symptoms Related to Cancers, Anxiety, and Insomnia
IRVINE, CA -- (Marketwired) -- 05/11/17 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces the release of a limited batch of cannabinoid-based suppositories for self-medicating, male and female patients. The suppositories aid with symptoms related to cancer, anxiety, insomnia, and severe pain relief. This Unisex Suppository Regimen Package, consisting of rectal suppositories, is the first of three regimen packages that will be released by CBIS to address the tremendous demand for cannabinoid-based medicines for self-medicating patients who require alternative delivery methods.
Suppositories are 50% to 70% more efficient and produce a more predictable effect than smoked or ingested cannabis. The rectal endothelium provides greater bioavailability than transcutaneous and oral delivery of cannabinoids. Suppositories can also be more effective in treating pelvic and lower gastrointestinal conditions. Additionally, suppositories are effective in individuals with nausea and vomiting, those with difficulty in swallowing pills (the elderly), those with wasting conditions especially in cases where appetite is inhibited, and in individuals on chemotherapy who find it difficult to manage oral medications.
"This is another ground-breaking product release. We expect our suppository regimens to help address a significant demand for cannabinoid-based medicines targeting several patient-specific indications. Through this limited release of unisex regimens to self-medicating patients, we expect to track the use of these products through the dispensary, and observe the effectiveness of this particular formulation and delivery system. This process, as part of an overall observation and testing protocol, will enable CBIS to develop products that can help the largest number of patients possible," stated Dr. Allen Herman, CBIS' Chief Medical Officer.
To enroll in this observational study, please contact Moonlight Cannabis Dispensary, located at 5801 E. Beverly Boulevard, Suite 100, Los Angeles, CA 90022. The dispensary's telephone number is 323.834.9420, and the email address is moonlightbeverly@gmail.com.
"The release of CBIS' Unisex Suppository Regimen is an important milestone as we build the company's portfolio of cannabinoid-based medicines. While this regimen is intended for men and women, we expect to release gender-specific suppositories and other products in the near future," stated Mr. Raymond C. Dabney, CBIS' President & CEO and Co-founder.
CBIS news out -- Cannabis Science Releases First Test Batch of Suppositories to Aid Self-Medicating Patients That Require Alternative Delivery Methods With Severe Pain and Symptoms Related to Cancers, Anxiety, and Insomnia
IRVINE, CA -- (Marketwired) -- 05/11/17 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces the release of a limited batch of cannabinoid-based suppositories for self-medicating, male and female patients. The suppositories aid with symptoms related to cancer, anxiety, insomnia, and severe pain relief. This Unisex Suppository Regimen Package, consisting of rectal suppositories, is the first of three regimen packages that will be released by CBIS to address the tremendous demand for cannabinoid-based medicines for self-medicating patients who require alternative delivery methods.
Suppositories are 50% to 70% more efficient and produce a more predictable effect than smoked or ingested cannabis. The rectal endothelium provides greater bioavailability than transcutaneous and oral delivery of cannabinoids. Suppositories can also be more effective in treating pelvic and lower gastrointestinal conditions. Additionally, suppositories are effective in individuals with nausea and vomiting, those with difficulty in swallowing pills (the elderly), those with wasting conditions especially in cases where appetite is inhibited, and in individuals on chemotherapy who find it difficult to manage oral medications.
"This is another ground-breaking product release. We expect our suppository regimens to help address a significant demand for cannabinoid-based medicines targeting several patient-specific indications. Through this limited release of unisex regimens to self-medicating patients, we expect to track the use of these products through the dispensary, and observe the effectiveness of this particular formulation and delivery system. This process, as part of an overall observation and testing protocol, will enable CBIS to develop products that can help the largest number of patients possible," stated Dr. Allen Herman, CBIS' Chief Medical Officer.
To enroll in this observational study, please contact Moonlight Cannabis Dispensary, located at 5801 E. Beverly Boulevard, Suite 100, Los Angeles, CA 90022. The dispensary's telephone number is 323.834.9420, and the email address is moonlightbeverly@gmail.com.
"The release of CBIS' Unisex Suppository Regimen is an important milestone as we build the company's portfolio of cannabinoid-based medicines. While this regimen is intended for men and women, we expect to release gender-specific suppositories and other products in the near future," stated Mr. Raymond C. Dabney, CBIS' President & CEO and Co-founder.
(0)
(0)